Navigation Links
QLT reports initial proof of concept data for punctal plug delivery technology
Date:5/12/2008

Small study supports the potential for QLT's drug elution technology to

reduce and sustain intraocular pressure

VANCOUVER, May 12 /PRNewswire-FirstCall/ - QLT Inc. (NASDAQ: QLTI; TSX: QLT) announced today results from a proof of concept trial conducted by QLT's wholly-owned subsidiary, QLT Plug Delivery, Inc., of its punctal plug drug delivery technology. The results demonstrated that QLT's drug elution technology was effective in controlling intraocular pressure (IOP) and was well tolerated.

The proof of concept, open label study was initiated to determine if a sustained administration of latanoprost using the Company's punctal plug drug delivery technology could lead to a reduction in IOP over 90 days when administered using a conventional plug design. Five patients (10 eyes) with glaucoma or ocular hypertension were enrolled at a single center. The primary efficacy endpoint was measurement of IOP. At baseline, the mean IOP was 23mmHg for the 10 eyes treated. At 90 day follow-up, the mean IOP was reduced to 17mmHg for the six eyes that remained. Data from two patients were excluded due to loss of plugs. No significant adverse events were reported.

"We are very pleased to report positive results from this preliminary proof of concept trial", said Bob Butchofsky, President and Chief Executive Officer of QLT. "Although the number of patients is small, we are encouraged by the clinically meaningful reduction in IOP that was observed and sustained for approximately 90 days. We look forward to providing you with additional details from this study at our Annual General Meeting on Wednesday, May 14."

The objective of QLT's punctal plug program is to demonstrate that the Company's drug elution technology leads to a statistically significant reduction in IOP for 90 days and that its proprietary punctal plug design can be retained comfortably in a high percentage of patients during that time period. The results presented t
'/>"/>

SOURCE QLT Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Neurobiological Technologies Reports Third Quarter Financial Results
2. Bionovo Reports First Quarter 2008 Financial Results
3. WorldHeart Reports an Event of Default Under the Note Issued to Abiomed, Resignation of One of Its Board of Directors, and Results of Shareholder Vote at Its Annual Shareholders Meeting
4. Cardium Reports on First Quarter 2008 Highlights and Financial Results
5. Novavax Reports First Quarter 2008 Financial Results
6. Warner Chilcott Reports Operating Results for the Quarter ended March 31, 2008 and Updates 2008 Full Year Guidance
7. Biodel Inc. Reports Second Quarter Fiscal Year 2008 Financial Results
8. Pharmos Corporation Reports 2008 First Quarter Results
9. Halozyme Therapeutics Reports 2008 First Quarter Financial Results
10. Nuvelo Reports First Quarter 2008 Financial Results and Updated Outlook for 2008
11. Favrille Reports First Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... 23, 2014 Dr. Williams says, “Find ... on healthcare offers a three phase process that can ... delivery system that would go far beyond anything previously ... the delivery of healthcare.” , “Every effort to improve ... to provide discernable progress throughout that system because all ...
(Date:9/23/2014)... 23, 2014 New spin-out ... Innovations, Cambridge Innovation Capital and Johnson & Johnson ... genomics company focused on harnessing the potential of ... testing and treatment, today announced it has raised ... Innovations and including Cambridge Innovation Capital and Johnson ...
(Date:9/22/2014)... SANTA CLARA, Calif. , Sept. 22, ... WBMD ), the leading source of health information, today ... that provide novel insights regarding physician and patient ... care.  Dr. Eric Topol , a leading authority ... serves as both Editor-in-Chief of Medscape and Chief Academic ...
(Date:9/22/2014)... cell fragments whose job it is to stop bleeding, ... But they can "feel" the physical environment around them, ... Platelets respond to surfaces with greater stiffness by increasing ... other platelets and other components of the clotting system, ... give them credit for, in that they are able ...
Breaking Biology Technology:Dr. Ira Williams Offers the Healthcare Solution Necessary for Patient Safety Improvement 2Inivata Raises £4m to Realise the Potential of ctDNA Analysis to Improve Cancer Treatment Through Simple Blood Tests 2Inivata Raises £4m to Realise the Potential of ctDNA Analysis to Improve Cancer Treatment Through Simple Blood Tests 3Inivata Raises £4m to Realise the Potential of ctDNA Analysis to Improve Cancer Treatment Through Simple Blood Tests 4WebMD/Medscape Digital Technology Survey Reveals Unique Insights Into How Patients and Physicians Perceive the Role, Potential and Risks Associated with Digital Health Technologies 2WebMD/Medscape Digital Technology Survey Reveals Unique Insights Into How Patients and Physicians Perceive the Role, Potential and Risks Associated with Digital Health Technologies 3WebMD/Medscape Digital Technology Survey Reveals Unique Insights Into How Patients and Physicians Perceive the Role, Potential and Risks Associated with Digital Health Technologies 4Platelets modulate clotting behavior by 'feeling' their surroundings 2
... Genetic Test Provides Early Diagnosis of Mitochondrial Diseases ... MEDomics, LLC ( www.medomics.com ) announces ... diseases, a group of disorders that can result ... headaches, blindness, deafness, and diabetes. The MEDomics mitochondrial ...
... Caliper Life Sciences, Inc. (Nasdaq: CALP ) today ... House entitled, "Innovation for Experimentation" to be held June 17, ... the Investor Breakout Session from 2:30 - 4:00 p.m. EDT. ... feature presentations by Kevin Hrusovsky, President and CEO, as well ...
... N.J., June 8 A study in ... , published by Elsevier, demonstrates that the Hepascore(TM) liver ... diagnose and stage liver fibrosis in patients with chronic ... biopsy, the standard of care for staging fibrosis, in ...
Cached Biology Technology:MEDomics Announces MitoDx(TM), the First NextGen Mitochondrial Genome Diagnostic Test 2MEDomics Announces MitoDx(TM), the First NextGen Mitochondrial Genome Diagnostic Test 3Caliper Life Sciences to Webcast Investor Session of Open House 2Study Finds Noninvasive Blood Test for Liver Fibrosis May Alleviate Need for Liver Biopsies for Some Patients with Chronic Hepatitis C 2Study Finds Noninvasive Blood Test for Liver Fibrosis May Alleviate Need for Liver Biopsies for Some Patients with Chronic Hepatitis C 3Study Finds Noninvasive Blood Test for Liver Fibrosis May Alleviate Need for Liver Biopsies for Some Patients with Chronic Hepatitis C 4
(Date:9/23/2014)... -- Newest Market IPO,s and exchange ... significant investor attention with news concerning shareholder updates and new ... NXT-ID, Inc. (NASDAQ: NXTD ), Alibaba Group Holding ... MBLY ), GoPro, Inc. (NASDAQ: GPRO ) ... (NASDAQ: NXTD ) recently completed an essential round ...
(Date:9/23/2014)... parasitic DNA fragments called "jumping genes" that insert themselves ... And that phenomenon can result in age-related diseases such ... now report that the "jumping genes" in mice become ... stops keeping them in check in order to take ... today in Nature Communications , Professor of Biology ...
(Date:9/22/2014)... September 23, 2014 A new American Cancer Society ... Assistance Program (SNAP), previously known as the food ... with income eligible non-participants. The authors say the ... at enhancing the dietary quality of SNAP participants. ... individuals and households with the resources to obtain ...
Breaking Biology News(10 mins):Latest Blockbuster IPOs and Up Listings for Global Tech Stocks Attracting Major Attention as Traders Focus on Key Economic Data Due this Week 2Latest Blockbuster IPOs and Up Listings for Global Tech Stocks Attracting Major Attention as Traders Focus on Key Economic Data Due this Week 3Latest Blockbuster IPOs and Up Listings for Global Tech Stocks Attracting Major Attention as Traders Focus on Key Economic Data Due this Week 4Latest Blockbuster IPOs and Up Listings for Global Tech Stocks Attracting Major Attention as Traders Focus on Key Economic Data Due this Week 5Latest Blockbuster IPOs and Up Listings for Global Tech Stocks Attracting Major Attention as Traders Focus on Key Economic Data Due this Week 6Latest Blockbuster IPOs and Up Listings for Global Tech Stocks Attracting Major Attention as Traders Focus on Key Economic Data Due this Week 7A multi-function protein is key to stopping genomic parasites from 'jumping' 2Federal food program puts food on the table, but dietary quality could be improved 2
... Calif., June 6 Communication,Intelligence Corporation (the "Company") ... signature solutions for business process,automation in the financial ... announced today that it has closed a financing, ... LLC (the "Investor")., As part of the ...
... basic questions about how life originated and has ... Foundation,s (NSF) Division of Environmental Biology (DEB). Ranging ... NSF,s awards for these studies will help resolve ... responses to environmental changes, including climate change. ...
... it was black as night. It was May 19, 1780 ... at hand. Accounts of that day, which became known as ... candlelight, night birds coming out to sing, flowers folding their ... has been solved by researchers at the University of Missouri ...
Cached Biology News:Communication Intelligence Corporation Closes $3.6 Million Financing 2Communication Intelligence Corporation Closes $3.6 Million Financing 3Communication Intelligence Corporation Closes $3.6 Million Financing 4National Science Foundation funds research addressing enduring questions of life 2National Science Foundation funds research addressing enduring questions of life 3National Science Foundation funds research addressing enduring questions of life 4Mystery of infamous 'New England Dark Day' solved by 3 rings 2
D-biotin *50 mM aqueous solution* Secondary Detection Biotin–Avidin Detection Reagents Other...
Endothelin-converting enzyme 1 (EC 3.4.24.71) (ECE-1). [Source:Uniprot/SWISSPROT;Acc:P42892] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
X-Gal (5-Bromo-4-Chloro-3-Indoyl-beta -D-Galactopyranoside)...
...
Biology Products: